Home About Clinical Research News Insights Podcasts Videos SCOPE Events

Stay Connected to Clinical Research—All Year Long

SCOPE 365 is the year-round digital extension of SCOPE, bringing clinical research professionals continuous access to insights, live virtual meetups, expert interviews, and premium intelligence products. It’s a centralized hub designed to help sponsors, CROs, sites, and solution providers stay on the pulse of the industry, elevate thought leadership, and maintain momentum between SCOPE’s global conferences.

Latest In Clinical Trials

Embedding Research Into Routine Care: The Next Phase of Trial Delivery

Insights from SCOPE | Embedding clinical research into routine care can expand access, reduce patient burden, and improve scalability without compromising oversight. Explore how integrated care pathways, hub-and-spoke models, and pragmatic protocol design are reshaping the next phase of trial delivery. more...

June 11, 2026
Urine Liquid Biopsy Shows Strong Promise for Guiding Bladder Cancer Treatment — Clinical Trials on the Horizon

Clinical Research News | A novel urine-based liquid biopsy developed at Stanford University is showing remarkable accuracy in predicting bladder cancer recurrence and may soon reshape how clinical trials enroll and treat patients. The test, developed by urologic oncologist Joseph Liao, M.D., and colleagues, filters out age-related background mutations in urine to produce a cleaner, more reliable signal for detecting residual cancer after surgery and immunotherapy. more...

June 11, 2026
Digital Tools at Sites: Closing the Perception Gap

Insights from SCOPE | Sponsors and sites often see digital adoption differently. Explore how misaligned assumptions, workflow gaps, and integration challenges shape real-world site technology use — and why early collaboration is essential to making digital tools reduce burden instead of increasing it. more...

June 09, 2026
The Scope of Things: Measuring Equity in Cancer Care

Clinical Research News | In the latest episode of The Scope of Things, Eugene Manley, Jr., founder and CEO of the STEMM & Cancer Health Equity Foundation, explains how underrepresented populations, including Black, Hispanic, Indigenous, rural, low-income, immigrant, underinsured, and uninsured communities, are less likely to receive guideline-aligned biomarker testing and less likely to be asked about clinical trial participation at all. more...

June 09, 2026
Decentralization as an Operating Model, Not a Feature Set

Insights from SCOPE | Decentralization only delivers real value when it’s designed as an operating model, not a collection of tools. Explore how flexible, community-integrated trial delivery models are expanding access, reducing burden, and reshaping how research is embedded into routine care. more...

June 04, 2026
Regulatory Outlook in Diagnostics Innovative and Uncertain

Clinical Research News | The diagnostics industry is at the intersection of enormous clinical development and technological change, enabling first-ever detection milestones heavily driven by artificial intelligence and multi-biomarker tests. But it has increasingly been coming into conflict with a decades-old regulatory system that didn’t anticipate these technological changes and a political environment that favors U.S. competition and innovation but is also interested in cutting the budget. more...

June 04, 2026